The future of cancer-killing viruses lies in their potential to augment cell and antibody immunotherapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
16 June 2015
In Table 1 of this article, the name of the oncolytic virus being developed by DNAtrix should have read 'DNX-2401'. This has been corrected in the online version of the article.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Dolgin, E. Oncolytic viruses get a boost with first FDA-approval recommendation. Nat Rev Drug Discov 14, 369–371 (2015). https://doi.org/10.1038/nrd4643
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4643
This article is cited by
-
Thermal immuno-nanomedicine in cancer
Nature Reviews Clinical Oncology (2023)
-
Erratum: Oncolytic viruses get a boost with first FDA-approval recommendation
Nature Reviews Drug Discovery (2015)
-
Oncolysis by paramyxoviruses: preclinical and clinical studies
Molecular Therapy - Oncolytics (2015)
-
Regulators approve the first cancer-killing virus
Nature Reviews Drug Discovery (2015)